Table 2. Site(s) of first progressive disease.
| Site | Chemotherapy alone (n=48) | Chemotherapy+cetuximab (n=61) |
|---|---|---|
| Preoperative progression | 13 | 15 |
| Liver only | 10 (77%) | 8 (53%) |
| Lung only | 1 (8%) | 0 |
| Locoregional only | 0 | 1 (7%) |
| Peritoneal only | 1 (8%) | 1 (7%) |
| Nodal | 0 | 0 |
| Multi-site | 0 | 5 (33%) |
| Unknowna | 1 (8%) | 0 |
| Postoperative progression | 35 | 46 |
| Liver only | 19 (54%) | 22 (47%) |
| Lung only | 8 (23%) | 8 (17%) |
| Locoregional only | 1 (3%) | 3 (7%) |
| Peritoneal only | 2 (6%) | 0 |
| Nodal | 1 (3%) | 4 (9%) |
| Multi-site | 4 (11%) | 9 (20%) |
a
Patient withdrew from trial at the time of progression.